MX2021001264A - Métodos para tratar la vejiga hiperactiva con el uso de trospio. - Google Patents

Métodos para tratar la vejiga hiperactiva con el uso de trospio.

Info

Publication number
MX2021001264A
MX2021001264A MX2021001264A MX2021001264A MX2021001264A MX 2021001264 A MX2021001264 A MX 2021001264A MX 2021001264 A MX2021001264 A MX 2021001264A MX 2021001264 A MX2021001264 A MX 2021001264A MX 2021001264 A MX2021001264 A MX 2021001264A
Authority
MX
Mexico
Prior art keywords
methods
trospium
overactive bladder
bladder
treating overactive
Prior art date
Application number
MX2021001264A
Other languages
English (en)
Inventor
Dennis Giesing
Original Assignee
Taris Biomedical Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taris Biomedical Llc filed Critical Taris Biomedical Llc
Publication of MX2021001264A publication Critical patent/MX2021001264A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/02—General characteristics of the apparatus characterised by a particular materials
    • A61M2205/0216—Materials providing elastic properties, e.g. for facilitating deformation and avoid breaking
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/02—General characteristics of the apparatus characterised by a particular materials
    • A61M2205/0266—Shape memory materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2210/00—Anatomical parts of the body
    • A61M2210/10—Trunk
    • A61M2210/1078—Urinary tract
    • A61M2210/1085—Bladder

Abstract

La presente solicitud proporciona métodos para tratar la vejiga hiperactiva y métodos para entrenar o reentrenar la vejiga, prolongar el alivio de síntomas, mejorar la calidad de vida y/o para el remodelado neuronal en un individuo que tiene vejiga hiperactiva, mediante la administración de una cantidad eficaz de trospio localmente a la vejiga del individuo durante al menos aproximadamente 24 horas.
MX2021001264A 2018-08-01 2019-07-31 Métodos para tratar la vejiga hiperactiva con el uso de trospio. MX2021001264A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862713414P 2018-08-01 2018-08-01
US201962850481P 2019-05-20 2019-05-20
PCT/US2019/044478 WO2020028554A1 (en) 2018-08-01 2019-07-31 Methods of treating overactive bladder using trospium

Publications (1)

Publication Number Publication Date
MX2021001264A true MX2021001264A (es) 2021-07-02

Family

ID=69232612

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021001264A MX2021001264A (es) 2018-08-01 2019-07-31 Métodos para tratar la vejiga hiperactiva con el uso de trospio.

Country Status (10)

Country Link
US (2) US11464734B2 (es)
EP (1) EP3829582A4 (es)
JP (1) JP2021532155A (es)
KR (1) KR20210039403A (es)
CN (1) CN112839653A (es)
AU (1) AU2019315957A1 (es)
BR (1) BR112021001337A2 (es)
CA (1) CA3107461A1 (es)
MX (1) MX2021001264A (es)
WO (1) WO2020028554A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020000832A2 (pt) 2017-07-25 2020-07-21 Taris Biomedical Llc métodos para tratar metástase tumoral
CN111787926A (zh) 2017-11-08 2020-10-16 塔里斯生物医药公司 使用吉西他滨对膀胱癌进行治疗和维持疗法的方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE59600683D1 (de) 1996-11-27 1998-11-19 Pfleger R Chem Fab Verwendung von Trospiumchlorid zur Herstellung eines Arzneimittels zur Behandlung von Blasenkrankheiten
MX2013000002A (es) * 2001-07-27 2013-04-29 Teva Womens Health Inc Metodos de tratamiento de condiciones patologicas asociadas con vejiga hiperactiva.
US20060058777A1 (en) 2002-12-11 2006-03-16 Pia Norup Nielsen Urinary catheter device with a pharmaceutically active composition
AU2004206846B2 (en) 2003-01-16 2009-05-28 University Of Rochester Quaternary antimuscarinic compounds for the treatment of bladder diseases
ATE427108T1 (de) 2004-08-11 2009-04-15 Boehringer Ingelheim Pharma Anticholinergika enthaltende arzneimittel zur behandlung von krankheiten der ableitenden harnwege
WO2006101954A2 (en) * 2005-03-17 2006-09-28 Indevus Pharmaceuticals, Inc. Interstitial cystitis treatment
US7390816B2 (en) * 2005-06-21 2008-06-24 Bridge Pharma, Inc. Methods for treating urinary incontinence in patients suffering from memory disorders
CA2618349C (en) 2005-08-11 2016-05-31 Massachusetts Institute Of Technology Intravesical drug delivery device and method
EP1967202A1 (en) 2007-03-05 2008-09-10 AEterna Zentaris GmbH Use of LHRH Antagonists for the Treatment of Lower Urinary Tract Symptoms, in particular Overactive Bladder and/or Detrusor Overactivity
BRPI0820800B8 (pt) 2007-12-11 2021-06-22 Massachusetts Inst Technology dispositivo médico implantável para liberação controlada de droga
CN102176931B (zh) 2008-08-09 2015-03-04 麻省理工学院 治疗男性泌尿生殖组织和外周组织的可植入药物递送设备和方法
ES2401007T3 (es) 2009-06-26 2013-04-16 Taris Biomedical, Inc. Dispositivos de administración de fármaco implantables y procedimientos de fabricación de los mismos
US9017312B2 (en) 2009-09-10 2015-04-28 Taris Biomedical Llc Implantable device for controlled drug delivery
ES2867399T3 (es) 2009-12-17 2021-10-20 Taris Biomedical Llc Dispositivo implantable con tolerabilidad intravesical
PT2600800T (pt) 2010-08-05 2020-11-05 Taris Biomedical Llc Dispositivo de administração de drogas por stent ureteral, kit e método
WO2012048114A1 (en) 2010-10-06 2012-04-12 Taris Biomedical, Inc. Time-selective bioresorbable or collapsible drug delivery systems and methods
CA2823783C (en) 2011-01-10 2023-03-21 Taris Biomedical, Inc. Lidocaine regimen for the use of sustained treatment of bladder pain and irritative voiding
CN103379902B (zh) 2011-02-04 2015-11-25 塔里斯生物医药公司 用于低溶解度药物的控制释放的可植入装置
SI2890384T1 (sl) * 2012-08-31 2022-02-28 Taris Biomedical Llc Sistemi za dostavo zdravila in postopki za zdravljenje raka sečnega mehurja, ki obsegajo oksaliplatin
CA2882575C (en) 2012-08-31 2020-05-26 Dennis GIESING Drug delivery systems and methods for treatment of prostate
AU2013318146B2 (en) 2012-09-18 2018-05-10 Taris Biomedical Llc Drug delivery systems and methods for treatment of bladder voiding dysfunction|and other lower urinary tract disorders by using trospium
EP2719374A1 (en) * 2012-10-12 2014-04-16 Rheinisch-Westfälische Technische Hochschule (RWTH) Aachen Drug delivery device
JP2016508842A (ja) 2013-03-05 2016-03-24 タリス バイオメディカル エルエルシー 装置の開口部を通じて制御された薬物放出のための薬物送達装置及び方法
RU2666684C2 (ru) 2013-03-15 2018-09-11 ТАРИС Биомедикал ЛЛК Устройство для доставки лекарственных средств с проницаемым для лекарственного средства компонентом и способ доставки лекарственных средств
KR102339132B1 (ko) 2013-03-15 2021-12-13 타리스 바이오메디컬 엘엘씨 약물 전달 장치 및 약물 전달 방법
CN113413393A (zh) 2013-08-19 2021-09-21 塔里斯生物医药公司 多单元药物递送装置和方法
CA2929554A1 (en) 2013-11-05 2015-05-14 Taris Biomedical Llc Osmotic drug delivery devices, kits, and methods
EP3517099B1 (en) 2014-06-26 2022-12-28 TARIS Biomedical LLC Intravesical drug delivery devices and methods including elastic polymer-drug matrix systems
WO2016172704A1 (en) 2015-04-23 2016-10-27 Taris Biomedical Llc Drug delivery devices with drug-permeable component and methods
ES2873084T3 (es) 2017-02-01 2021-11-03 Taris Biomedical Llc Dispositivos para la administración de fármacos in vivo
BR112020000832A2 (pt) 2017-07-25 2020-07-21 Taris Biomedical Llc métodos para tratar metástase tumoral

Also Published As

Publication number Publication date
AU2019315957A1 (en) 2021-02-18
EP3829582A1 (en) 2021-06-09
EP3829582A4 (en) 2022-04-27
KR20210039403A (ko) 2021-04-09
JP2021532155A (ja) 2021-11-25
US20200060966A1 (en) 2020-02-27
US11464734B2 (en) 2022-10-11
WO2020028554A1 (en) 2020-02-06
CN112839653A (zh) 2021-05-25
CA3107461A1 (en) 2020-02-06
BR112021001337A2 (pt) 2021-04-20
US20230075003A1 (en) 2023-03-09

Similar Documents

Publication Publication Date Title
MX2020001732A (es) Tratamiento de las afecciones del sistema nervioso central.
EP4218804A3 (en) Use of myostatin inhibitors and combination therapies
MX2020008906A (es) Compuestos con actividad inductora de ferroptosis y métodos de uso de estos.
MX2019013279A (es) Metodos de tratamiento del sindrome de doose utilizando fenfluramina.
MX2020005547A (es) Moduladores de la actividad del complemento.
WO2019246262A3 (en) Methods of treating or inhibiting onset of huntington's disease
PH12020552088A1 (en) Vmat2 inhibitor compounds, compositions, and methods relating thereto
JOP20200035A1 (ar) تركيبات حمض أميني لعلاج الإصابات العصبية
MY194462A (en) Composition for Promoting Differentiation of and Protecting Neural Stem Cells and Method for Inducing Neural Regeneration using same
MX2021002754A (es) Tratamiento del autismo y trastornos dentro del espectro del autismo con composiciones de biotina.
PH12019500177A1 (en) Treatment and prevention of sleep disorders
MX2021001264A (es) Métodos para tratar la vejiga hiperactiva con el uso de trospio.
EP4279127A3 (en) Growth differentiation factor 15 as biomarker for metformin
PH12021550047A1 (en) USE OF sGC STIMULATORS FOR THE TREATMENT OF MITOCHONDRIAL DISORDERS
PH12019502174A1 (en) Modulators of pcsk9 expression
MX2023000187A (es) Dosificacion de vibegron para el tratamiento de vejiga sobreactiva.
MX2022004524A (es) Tratamiento génico para la enfermedad de alzheimer.
PH12020551995A1 (en) Modulator of apol1 expression
MX2021009488A (es) Uso de vibegron para tratar la vejiga hiperactiva.
MX2021011598A (es) Uso de mir101 o mir128 en el tratamiento de trastornos convulsivos.
PH12021550741A1 (en) Vibegron for the treatment of overactive bladder symptoms
WO2020021332A3 (en) Injection techniques for the treatment of cellulite
WO2020021330A3 (en) Injection techniques for the treatment of cellulite
MX2022004945A (es) Tratamiento de afecciones epilépticas con moduladores del receptor gabaa.
CL2021000743A1 (es) Métodos para tratar trastornos mieloproliferativos